Product
CD19 t-haNK
Aliases
Rituximab
1 clinical trial
1 indication
Indication
Non-Hodgkin LymphomaClinical trial
Open-Label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With Rituximab in Subjects With Selected CD19+ and CD20+ Relapsed/Refractory B-Cell Non-Hodgkin LymphomaStatus: Not yet recruiting, Estimated PCD: 2026-03-30